
PALSONIFY shows durable, consistent control of acromegaly symptoms and tumor stability over two years.
Crinetics Pharmaceuticals presented long-term data from PATHFNDR-1 and PATHFNDR-2 studies showing that PALSONIFY (paltusotine), an oral once-daily treatment for acromegaly, maintained stable IGF-1 levels, controlled symptoms, and stabilized or reduce...


